ES2271958T3
(es)
*
|
1996-09-04 |
2007-04-16 |
Intertrust Technologies Corp |
Sistemas, procedimientos y tecnicas fiables de soporte de infraestructuras para comercio electronico seguro, transacciones electronicas, control y automatizacion de procedimientos comerciales, informatica distribuida y gestion de derechos.
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
DK2041139T3
(da)
*
|
2006-04-26 |
2012-01-16 |
Genentech Inc |
Farmaceutiske forbindelser
|
CA2650303C
(en)
*
|
2006-04-26 |
2015-03-24 |
F. Hoffmann-La Roche Ag |
Thienopyrimidine pharmaceutical compounds and their use
|
AR064154A1
(es)
*
|
2006-12-07 |
2009-03-18 |
Piramed Ltd |
Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
|
RU2468027C2
(ru)
|
2006-12-07 |
2012-11-27 |
Ф. Хоффманн-Ля Рош Аг |
Ингибиторы фосфоинозитид-3-киназы и способы их применения
|
CN101679456B
(zh)
*
|
2007-06-12 |
2012-09-05 |
霍夫曼-拉罗奇有限公司 |
噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
|
EP2205242B1
(en)
*
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
JP5736171B2
(ja)
|
2007-09-24 |
2015-06-17 |
ジェネンテック, インコーポレイテッド |
チアゾロピリミジンpi3k阻害剤化合物および使用方法
|
JP5348725B2
(ja)
*
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
GB0721095D0
(en)
*
|
2007-10-26 |
2007-12-05 |
Piramed Ltd |
Pharmaceutical compounds
|
WO2009094224A1
(en)
*
|
2008-01-25 |
2009-07-30 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
|
ES2494365T3
(es)
*
|
2008-01-30 |
2014-09-15 |
Genentech, Inc. |
Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
|
AR070865A1
(es)
*
|
2008-03-18 |
2010-05-12 |
Genentech Inc |
Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
|
CN102066365A
(zh)
|
2008-06-19 |
2011-05-18 |
米伦纽姆医药公司 |
噻吩或噻唑衍生物和其作为pi3k抑制剂的用途
|
RU2473549C2
(ru)
*
|
2008-07-31 |
2013-01-27 |
Дженентек, Инк. |
Пиримидиновые соединения, композиции и способы применения
|
RS53350B
(en)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
|
RU2519200C2
(ru)
|
2008-10-01 |
2014-06-10 |
Новартис Аг |
Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
SI3372605T1
(sl)
|
2008-10-22 |
2022-03-31 |
Array Biopharma, Inc. |
Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze
|
ME02230B
(me)
|
2009-01-08 |
2016-02-20 |
Curis Inc |
Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
CA2750935A1
(en)
|
2009-01-30 |
2010-08-12 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and their use as pi3k inhibitors
|
US8796314B2
(en)
|
2009-01-30 |
2014-08-05 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
CA2753285A1
(en)
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
CN102361878A
(zh)
|
2009-03-24 |
2012-02-22 |
住友化学株式会社 |
用于制备硼酸酯化合物的方法
|
TW201038567A
(en)
*
|
2009-03-27 |
2010-11-01 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
CN102459272B
(zh)
|
2009-05-27 |
2014-08-06 |
健泰科生物技术公司 |
对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
|
CA2772371A1
(en)
|
2009-05-27 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
SG176959A1
(en)
*
|
2009-06-24 |
2012-01-30 |
Genentech Inc |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
US8435976B2
(en)
*
|
2009-09-08 |
2013-05-07 |
F. Hoffmann-La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
ES2557316T3
(es)
*
|
2009-09-08 |
2016-01-25 |
F. Hoffmann-La Roche Ag |
Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
|
CN102030770B
(zh)
*
|
2009-09-25 |
2012-10-31 |
北京大学 |
一种芳香硼酸酯化合物的制备方法
|
EP2784078A1
(en)
|
2009-09-28 |
2014-10-01 |
F. Hoffmann-La Roche AG |
Benzoxepin pi3k inhibitor compounds and methods of use
|
AU2010314287A1
(en)
*
|
2009-10-12 |
2012-05-03 |
F. Hoffmann-La Roche Ag |
Combinations of a PI3K inhibitor and a MEK inhibitor
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
AP2012006294A0
(en)
|
2009-11-05 |
2012-06-30 |
Rhizen Pharmaceuticals Sa |
Novel kinase modulators.
|
RU2515541C2
(ru)
*
|
2009-11-12 |
2014-05-10 |
Ф.Хоффманн-Ля Рош Аг |
N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
|
MX2012005463A
(es)
*
|
2009-11-12 |
2012-09-12 |
Hoffmann La Roche |
Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
|
AU2010338038B2
(en)
|
2009-12-31 |
2015-07-09 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Tricyclic compounds for use as kinase inhibitors
|
BR112012019459A2
(pt)
|
2010-02-03 |
2017-10-17 |
Signal Pharm Llc |
identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
|
WO2011101429A1
(en)
|
2010-02-22 |
2011-08-25 |
F. Hoffmann-La Roche Ag |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
EP3521291A1
(en)
|
2010-05-20 |
2019-08-07 |
Array Biopharma, Inc. |
Macrocyclic compounds as trk kinase inhibitors
|
CN103003279B
(zh)
*
|
2010-07-14 |
2015-09-23 |
弗·哈夫曼-拉罗切有限公司 |
对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
|
WO2012021615A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
MX2013001660A
(es)
|
2010-08-11 |
2013-06-03 |
Millenium Pharmaceuticals Inc |
Heteroarilos y usos de los mismos.
|
WO2012021611A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
WO2012051410A2
(en)
|
2010-10-13 |
2012-04-19 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
CN105859735B
(zh)
|
2010-12-16 |
2018-03-09 |
霍夫曼-拉罗奇有限公司 |
三环pi3k抑制剂化合物和使用方法
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
EP2667874A4
(en)
*
|
2011-01-27 |
2014-07-30 |
Univ Princeton |
MTOR KINASE INHIBITORS AS ANTIVIRAL AGENTS
|
CN103476767B
(zh)
|
2011-02-09 |
2015-06-10 |
弗·哈夫曼-拉罗切有限公司 |
作为pi3激酶抑制剂的杂环化合物
|
WO2012126901A1
(en)
|
2011-03-21 |
2012-09-27 |
F. Hoffmann-La Roche Ag |
Benzoxazepin compounds selective for pi3k p110 delta and methods of use
|
CN105461736B
(zh)
|
2011-04-01 |
2018-06-12 |
柯瑞斯公司 |
具有锌结合位的磷脂酰肌醇3-激酶抑制剂
|
MX365160B
(es)
|
2011-05-04 |
2019-05-24 |
Rhizen Pharmaceuticals Sa |
Compuestos novedosos como moduladores de proteína cinasas.
|
US20130158023A1
(en)
|
2011-08-03 |
2013-06-20 |
Signal Pharmaceuticals, Llc |
Identification of gene expression as a predictive biomarker for lkb1 status
|
US20130096116A1
(en)
*
|
2011-10-13 |
2013-04-18 |
Genentech, Inc. |
Treatment of pharmacological-induced hypochlorhydria
|
WO2013152717A1
(zh)
|
2012-04-10 |
2013-10-17 |
上海昀怡健康管理咨询有限公司 |
稠合嘧啶类化合物,其制备方法,中间体,组合物和应用
|
CA2868392A1
(en)
|
2012-05-23 |
2013-11-28 |
Estelle DOUDEMENT |
Compositions and methods of obtaining and using endoderm and hepatocyte cells
|
BR112014028376A2
(pt)
|
2012-06-08 |
2018-04-24 |
Hoffmann La Roche |
métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
|
ES2647416T3
(es)
|
2012-07-04 |
2017-12-21 |
Rhizen Pharmaceuticals S.A. |
Inhibidores de PI3K delta selectivos
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
CN102924473B
(zh)
*
|
2012-11-05 |
2015-09-02 |
上海毕得医药科技有限公司 |
一种2-氯-7-碘噻吩并[3,2-d]嘧啶的制备方法
|
RU2015127037A
(ru)
|
2012-12-07 |
2017-01-11 |
Дзе Дженерал Хоспитал Корпорейшн |
Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
|
KR102271344B1
(ko)
|
2013-04-17 |
2021-07-01 |
시그날 파마소티칼 엘엘씨 |
디하이드로피라지노-피라진을 사용한 암의 치료
|
CN105392499B
(zh)
|
2013-04-17 |
2018-07-24 |
西格诺药品有限公司 |
用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
|
UA115805C2
(uk)
|
2013-04-17 |
2017-12-26 |
Сігнал Фармасьютікалз, Елелсі |
Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
CA2909625C
(en)
|
2013-04-17 |
2021-06-01 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
KR20160002792A
(ko)
|
2013-04-17 |
2016-01-08 |
시그날 파마소티칼 엘엘씨 |
암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
|
AU2014254050B2
(en)
|
2013-04-17 |
2018-10-04 |
Signal Pharmaceuticals, Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
CN105407892B
(zh)
|
2013-05-29 |
2019-05-07 |
西格诺药品有限公司 |
一种化合物的药物组合物、其固体形式及它们的使用方法
|
WO2015043398A1
(zh)
|
2013-09-30 |
2015-04-02 |
上海璎黎药业有限公司 |
稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
|
MX2016004964A
(es)
|
2013-10-16 |
2016-07-11 |
Shanghai Yingli Pharm Co Ltd |
Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
|
EP4062917A1
(en)
*
|
2013-12-20 |
2022-09-28 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
|
CN106661039B
(zh)
|
2014-02-28 |
2019-09-13 |
林伯士拉克许米公司 |
酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
|
CA2940576A1
(en)
|
2014-03-13 |
2015-09-17 |
F. Hoffmann-La Roche Ag |
Therapeutic combinations with estrogen receptor modulators
|
CA2946538A1
(en)
|
2014-04-04 |
2015-10-08 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US10004748B2
(en)
|
2014-05-21 |
2018-06-26 |
Genentech, Inc. |
Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib
|
EP3180349A4
(en)
|
2014-08-12 |
2018-08-22 |
Monash University |
Lymph directing prodrugs
|
GB201419102D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Imp Innovations Ltd |
Novel compounds
|
MX2017006412A
(es)
|
2014-11-16 |
2017-09-12 |
Array Biopharma Inc |
Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida.
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
CN106146352A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
Idelalisib中间体及其制备方法
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
EP3598134A1
(en)
|
2015-06-29 |
2020-01-22 |
F. Hoffmann-La Roche AG |
Methods of treatment with taselisib
|
US9650393B2
(en)
|
2015-07-02 |
2017-05-16 |
Genentech, Inc. |
Benzoxazepin oxazolidinone compounds and methods of use
|
EP3317283B1
(en)
|
2015-07-02 |
2019-04-03 |
H. Hoffnabb-La Roche Ag |
Benzoxazepin oxazolidinone compounds and methods of use
|
CN105147696A
(zh)
*
|
2015-07-08 |
2015-12-16 |
李荣勤 |
联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法
|
WO2017012559A1
(zh)
*
|
2015-07-21 |
2017-01-26 |
广州再极医药科技有限公司 |
稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
CA2997106A1
(en)
|
2015-09-08 |
2017-03-16 |
Monash University |
Lymph directing prodrugs
|
WO2017044720A1
(en)
|
2015-09-11 |
2017-03-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
CN108289866A
(zh)
|
2015-10-23 |
2018-07-17 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂和其用途
|
JP2018534296A
(ja)
|
2015-10-26 |
2018-11-22 |
ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. |
Trk阻害薬耐性がんにおける点変異およびそれに関連する方法
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
CN108473506B
(zh)
|
2015-12-31 |
2021-08-17 |
韩美药品株式会社 |
噻吩并嘧啶化合物的盐酸盐的结晶形式
|
EP3426244B1
(en)
|
2016-03-09 |
2023-06-07 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
US10954220B2
(en)
|
2016-03-09 |
2021-03-23 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
MX2018012163A
(es)
|
2016-04-04 |
2019-07-08 |
Loxo Oncology Inc |
Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirr olidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina- 1-carboxamida.
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
RS61463B1
(sr)
|
2016-05-18 |
2021-03-31 |
Loxo Oncology Inc |
Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
CA3027498A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2018071794A1
(en)
|
2016-10-14 |
2018-04-19 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
JP7082120B2
(ja)
|
2016-10-21 |
2022-06-07 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
WO2018106636A1
(en)
|
2016-12-05 |
2018-06-14 |
Raze Therapeutics, Inc. |
Shmt inhibitors and uses thereof
|
JP2020502238A
(ja)
|
2016-12-23 |
2020-01-23 |
バイスクルアールディー・リミテッド |
新規連結構造を有するペプチド誘導体
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
US10912750B2
(en)
|
2017-04-26 |
2021-02-09 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
JP7282045B2
(ja)
|
2017-06-22 |
2023-05-26 |
セルジーン コーポレイション |
B型肝炎ウイルス感染を特徴とする肝細胞癌の治療
|
US10899798B2
(en)
|
2017-06-26 |
2021-01-26 |
Bicyclerd Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
SG11202000714QA
(en)
|
2017-07-28 |
2020-02-27 |
Nimbus Lakshmi Inc |
Tyk2 inhibitors and uses thereof
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
US20200291096A1
(en)
|
2017-08-14 |
2020-09-17 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
CA3076613A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
CN109796465B
(zh)
*
|
2017-11-16 |
2020-07-14 |
华中科技大学同济医学院附属协和医院 |
靶向pet显像化合物、包含该化合物的显象剂及其制备方法和用途
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
CN112105385A
(zh)
|
2017-12-26 |
2020-12-18 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND THEIR USES
|
CA3089769A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
CN117304157A
(zh)
|
2018-02-27 |
2023-12-29 |
阿塔克斯生物制药有限公司 |
作为tcr-nck相互作用的抑制剂的色烯衍生物
|
JP7479293B2
(ja)
|
2018-04-24 |
2024-05-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プテリジノン化合物およびその使用
|
WO2019209759A1
(en)
|
2018-04-24 |
2019-10-31 |
Merck Patent Gmbh |
Antiproliferation compounds and uses thereof
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CN108997372B
(zh)
*
|
2018-07-31 |
2020-07-28 |
华中科技大学同济医学院附属协和医院 |
正电子显像用化合物、其中间体、制备方法和显像剂
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
Eif4e阻害剤およびその使用
|
WO2020055840A1
(en)
|
2018-09-11 |
2020-03-19 |
Curis Inc. |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
JP2022512779A
(ja)
|
2018-10-23 |
2022-02-07 |
バイスクルテクス・リミテッド |
二環式ペプチドリガンドおよびその使用
|
US11345654B2
(en)
|
2018-10-24 |
2022-05-31 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
JP2022516401A
(ja)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
AU2019389025A1
(en)
|
2018-11-30 |
2021-06-17 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
WO2020154474A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
EP3946462A1
(en)
|
2019-04-02 |
2022-02-09 |
BicycleTX Limited |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(zh)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202118770A
(zh)
|
2019-07-30 |
2021-05-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
JP2022548594A
(ja)
|
2019-09-11 |
2022-11-21 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Usp30阻害剤及びその使用
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
MX2022005215A
(es)
|
2019-11-01 |
2022-06-08 |
Navitor Pharm Inc |
Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
|
MX2022006807A
(es)
|
2019-12-05 |
2022-09-12 |
Anakuria Therapeutics Inc |
Análogos de rapamicina y usos de estos.
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics Inc |
IRAQ DEGRADERS AND USES THEREOF
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
TW202136242A
(zh)
|
2019-12-23 |
2021-10-01 |
美商凱麥拉醫療公司 |
Smarca降解劑及其用途
|
IL295362A
(en)
|
2020-02-05 |
2022-10-01 |
Puretech Lyt Inc |
Lipid drug inhibitors of neurosteroids
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
CA3171258A1
(en)
|
2020-03-19 |
2021-09-23 |
Nan JI |
Mdm2 degraders and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
AU2021327130A1
(en)
|
2020-08-17 |
2023-03-02 |
Bicycletx Limited |
Bicycle conjugates specific for Nectin-4 and uses thereof
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
TW202245789A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|